Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

Lake Street analyst Daniel Brims has initiated coverage on Spruce Biosciences (NASDAQ: SPRB) with a Buy rating. The analyst has set a price target of $149 for the company's stock.